Laboratorios Farmaceuticos Rovi (ROVI) Hisse Özeti
Laboratorios Farmaceuticos Rovi, S.A. İspanya'da, Avrupa Birliği'nde, OECD ülkelerinde ve uluslararası alanda farmasötik ürünler üretmekte, satmakta ve pazarlamaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 6/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 3/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 3/6 |
Ödüller
Risk Analizi
ROVI Community Fair Values
Create NarrativeSee what 52 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
€51.25
FV
13.2% aşırı değerlenmiş içsel indirim4.00%
Revenue growth p.a.
162
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Laboratorios Farmaceuticos Rovi, S.A. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | €58.00 |
| 52 Haftanın En Yüksek Seviyesi | €86.70 |
| 52 Haftanın En Düşük Seviyesi | €53.10 |
| Beta | 0.23 |
| 1 Aylık Değişim | 7.11% |
| 3 Aylık Değişim | -3.25% |
| 1 Yıllık Değişim | 0.96% |
| 3 Yıllık Değişim | 17.22% |
| 5 Yıllık Değişim | -12.25% |
| Halka arzdan bu yana değişim | 480.00% |
Son Haberler & Güncellemeler
Analiz Makalesi • Jul 31
We Think That There Are Issues Underlying Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings
Unsurprisingly, Laboratorios Farmaceuticos Rovi, S.A.'s ( BME:ROVI ) stock price was strong on the back of its healthy...Analiz Makalesi • Jul 26
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Released Its Half-Year Earnings: Here's What Analysts Think
Investors in Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) had a good week, as its shares rose 8.6% to close at...Recent updates
Analiz Makalesi • Jul 31
We Think That There Are Issues Underlying Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings
Unsurprisingly, Laboratorios Farmaceuticos Rovi, S.A.'s ( BME:ROVI ) stock price was strong on the back of its healthy...Analiz Makalesi • Jul 26
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Released Its Half-Year Earnings: Here's What Analysts Think
Investors in Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) had a good week, as its shares rose 8.6% to close at...
Anlatı Güncellemesi • Jun 18
ROVI: Contract Manufacturing Expansion And Dividend Capacity Will Support Future Share Returns
Analysts have trimmed their fair value estimate for Laboratorios Farmaceuticos Rovi stock from about €76.49 to roughly €75.38, citing a slightly less optimistic outlook on revenue growth, profit margins and future P/E multiples after recent downgrades from several firms. Analyst Commentary Recent commentary around Laboratorios Farmaceuticos Rovi focuses on how recent downgrades affect expectations for execution, valuation and growth, rather than on any single data point in isolation.Anlatı Güncellemesi • Jun 02
ROVI: Medium Term Contract Risks Will Still Support Future Returns
Analysts have trimmed the fair value estimate for Laboratorios Farmaceuticos Rovi from about €82.48 to €76.49 after recent downgrades flagged softer revenue growth assumptions, slightly lower profit margins and a modestly higher future P/E, with some noting medium term risks linked to Moderna exposure and declining vaccination volumes. Analyst Commentary Recent research has tilted more cautious on Laboratorios Farmaceuticos Rovi, with several downgrades pointing to a reassessment of growth, margins and risk tied to its partner exposure.Analiz Makalesi • Feb 09
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Anlatı Güncellemesi • Feb 03
ROVI: Slightly Higher Fair Value And P/E Will Support Future Returns
Analysts have nudged their price target for Laboratorios Farmaceuticos Rovi slightly higher, with a modest upward revision in fair value tied to refreshed assumptions for revenue, profit margins and future P/E multiples. Valuation Changes Fair Value: Adjusted slightly higher from €81.97 to €82.48 per share, reflecting refreshed model assumptions.Anlatı Güncellemesi • Jan 20
ROVI: Stable Returns And Slightly Higher Multiple Will Support Future Earnings
Analysts have nudged up their fair value estimate for Laboratorios Farmaceuticos Rovi from €80.96 to €81.97, citing slightly higher revenue growth assumptions, a small adjustment in expected profit margins, and a modestly higher future P/E multiple as key drivers of the new target. Valuation Changes Fair Value Estimate was adjusted slightly from €80.96 to €81.97, reflecting a small uplift in the modelled valuation.Anlatı Güncellemesi • Jan 05
ROVI: Stable Returns And Margins Will Support Stronger Future Earnings
Analysts have kept their price target for Laboratorios Farmaceuticos Rovi unchanged, citing stable assumptions around a fair value of €80.96, a discount rate of 7.65%, revenue growth of 12.59%, a profit margin of 23.81% and a future P/E of 20.93 to support their view. Valuation Changes Fair Value: The fair value estimate remains unchanged at €80.96 per share, reflecting the same core valuation outcome as before.Anlatı Güncellemesi • Dec 15
ROVI: Stable Margins And Growth Outlook Will Support Stronger Future Earnings
Analysts have modestly adjusted their price targets for Laboratorios Farmaceuticos Rovi, now valuing the shares around €80.96. They reiterate expectations for solid double digit revenue growth, resilient profit margins, and a stable long term valuation multiple.Anlatı Güncellemesi • Dec 01
ROVI: Increasing Profit Margins Will Drive Stronger Earnings Outlook
Analysts have modestly increased their price target for Laboratorios Farmaceuticos Rovi to €80.96 per share. They cite improving profit margin forecasts as the primary driver of the change.Anlatı Güncellemesi • Nov 17
ROVI: Revenue Acceleration Projected To Drive Upside Despite Margin Pressure
Analysts have raised their price target for Laboratorios Farmaceuticos Rovi from €79.41 to €80.96. They cite improved revenue growth projections, despite slightly lower profit margins and a marginal increase in the discount rate.Analiz Makalesi • Nov 09
Here's What Analysts Are Forecasting For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) After Its Third-Quarter Results
It's been a mediocre week for Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) shareholders, with the stock dropping...Analiz Makalesi • Nov 06
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Jun 14
Laboratorios Farmaceuticos Rovi's (BME:ROVI) Dividend Will Be Reduced To €0.7574
Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) has announced that on 16th of July, it will be paying a dividend...Analiz Makalesi • May 27
Laboratorios Farmaceuticos Rovi's (BME:ROVI) Shareholders Will Receive A Smaller Dividend Than Last Year
Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) has announced that on 16th of July, it will be paying a dividend...Analiz Makalesi • Feb 09
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Yeni Anlatı • Dec 26
Okedi Expansion And Heparin Integration To Boost Revenue And Net Margins
Focus on Okedi and enoxaparin indicates potential revenue growth and improved profit margins from European development and heparin sales volume.Analiz Makalesi • Nov 10
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
There's been a notable change in appetite for Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) shares in the week...Analiz Makalesi • Oct 21
With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For
When close to half the companies in Spain have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Analiz Makalesi • Aug 29
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Jul 15
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Laboratorios Farmaceuticos Rovi fair value estimate is €146...Analiz Makalesi • Jun 17
We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet
Key Insights Laboratorios Farmaceuticos Rovi will host its Annual General Meeting on 24th of June Salary of €743.0k is...Analiz Makalesi • May 08
Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price
When close to half the companies in Spain have price-to-earnings ratios (or "P/E's") below 16x, you may consider...Analiz Makalesi • Apr 17
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analiz Makalesi • Feb 14
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Laboratorios Farmaceuticos Rovi fair value estimate is €92.64...Analiz Makalesi • Dec 21
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Nov 03
Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?
Key Insights The projected fair value for Laboratorios Farmaceuticos Rovi is €73.44 based on 2 Stage Free Cash Flow to...Analiz Makalesi • Aug 26
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Jul 14
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate
Key Insights Laboratorios Farmaceuticos Rovi's estimated fair value is €52.88 based on 2 Stage Free Cash Flow to Equity...Analiz Makalesi • May 26
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analiz Makalesi • May 05
Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analiz Makalesi • Apr 11
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate
Key Insights Laboratorios Farmaceuticos Rovi's estimated fair value is €51.68 based on 2 Stage Free Cash Flow to Equity...Analiz Makalesi • Feb 22
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Dec 10
An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued
In this article we are going to estimate the intrinsic value of Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) by...Analiz Makalesi • Nov 04
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Sep 15
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analiz Makalesi • Aug 28
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Laboratorios...Hissedar Getirileri
| ROVI | ES Pharmaceuticals | ES Pazar | |
|---|---|---|---|
| 7D | -0.6% | -1.1% | -1.3% |
| 1Y | 1.0% | -0.5% | 27.1% |
Getiri vs. Endüstri: ROVI geçen yıl % -0.5 oranında getiri sağlayan Spanish Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: ROVI geçen yıl % 27.1 oranında getiri sağlayan Spanish Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| ROVI volatility | |
|---|---|
| ROVI Average Weekly Movement | 2.5% |
| Pharmaceuticals Industry Average Movement | 2.6% |
| Market Average Movement | 3.0% |
| 10% most volatile stocks in ES Market | 6.3% |
| 10% least volatile stocks in ES Market | 0.6% |
İstikrarlı Hisse Senedi Fiyatı: ROVI son 3 ayda Spanish piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: ROVI 'nin haftalık oynaklığı ( 3% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1946 | 2,470 | Juan Lopez-Belmonte Encina | www.rovi.es |
Laboratorios Farmaceuticos Rovi, S.A. İspanya'da, Avrupa Birliği'nde, OECD ülkelerinde ve uluslararası alanda farmasötik ürünler üretmekte, satmakta ve pazarlamaktadır. Şirket, Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler ve Volutsa dahil olmak üzere reçeteli ürünler sunmaktadır. Ayrıca Iomeron ve Iopamiro, Multihance ve Y Prohance, Sonovue, Empowercta+, Empowermr ve CT Express gibi hastane ürünleri; Fibrilin markası altında kateter bakımı ve Sodyum Heparin Rovi sağlamaktadır.
Laboratorios Farmaceuticos Rovi, S.A. Temel Bilgiler Özeti
| ROVI temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | €2.97b |
| Kazançlar(TTM) | €185.18m |
| Gelir(TTM) | €773.05m |
16.0x
F/K Oranı3.8x
P/S OranıROVI aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| ROVI gelir tablosu (TTM) | |
|---|---|
| Gelir | €773.05m |
| Gelir Maliyeti | €272.63m |
| Brüt Kâr | €500.42m |
| Diğer Giderler | €315.24m |
| Kazançlar | €185.18m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 3.62 |
| Brüt Marj | 64.73% |
| Net Kâr Marjı | 23.95% |
| Borç/Özkaynak Oranı | 15.0% |
ROVI uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
1.7%
Mevcut Temettü Verimi26%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/18 08:27 |
| Gün Sonu Hisse Fiyatı | 2026/08/18 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Laboratorios Farmaceuticos Rovi, S.A. 13 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |